Update on CVD and Microvascular Complications in T2D
|
|
- Jemimah Knight
- 5 years ago
- Views:
Transcription
1 Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
2 Commercial Interests Board of Directors Member Dexcom, Moerae Matrix, Paean Therapeutics, VasoPrep Surgical Scientific Advisory Board Member Diavacs, Halozyme, Orgenesis, Sekris, Valeritas, Viacyte Advisor or Consultant Boheringer Ingelheim, Bristol-Myers Squibb/Astra-Zeneca, Elcelyx, Eli Lilly, Ideal Life, Intarcia, Julphar, Roche, Sanofi Stock or Option Holder Dexcom, Ideal Life, Moerae Matrix, Paean Therapeutics, Patton Medical Devices, Tandem Diabetes Care, VasoPrep Surgical Research Support (to University of Miami) Halozyme, Mesoblast
3 Adolescent Renal & Cardiovascular Disease Protection in Type 1 Diabetes AdDIT Study: David Dunger CVD Outcome Studies in Type 2 Diabetes: Angelyn Bethel Prevention of Cardio-Renal Complications: David Maahs
4 CVD in Diabetes
5 Glucose Paradox Glucose levels & hyperglycemic states are closely linked to increased CVD risk Definitive evidence that improving glucose control decreases major CVD events remains elusive
6 Effect of Intensive Glucose Lowering on Macrovascular Complications in T2DM ACCORD ADVANCE VADT Non-fatal MI Primary outcome Non-fatal stroke Non-fatal MI Non-fatal MI CVD death Non-fatal stroke Non-fatal stroke Hospitalization for CVD death CVD death CHF Revascularization HR for primary outcome (95% CI) 0.90 ( ) 0.94 ( ) 0.87 ( ) HR for mortality (95% CI) 1.22 ( )* 1.46)* 0.93 ( ) ( ) *p=0.04 VADT = Veterans Affairs Diabetes Trial VADT study ADVANCE Collaborative Group. N Engl J Med 2008;358: ACCORD Study Group. N Engl J Med 2008;358: VADT Study Group. N Engl J Med 2009;360:
7 Glucose Paradox Glucose levels & hyperglycemic states are closely linked to increased CVD risk Definitive evidence that improving glucose control decreases major CVD events remains elusive Possible reasons: Intervention too late Studies too short, too small
8 Comparison of ACCORD, ADVANCE, VADT Characteristic ACCORD ADVANCE VADT N 10,251 11,140 1,791 Mean Age Duration of T2DM 10 yr 8 yr 11.5 yr History of CVD 35% 32% 40% BMI Baseline A1C 8.3% 7.5% 9.4% Study Duration ACCORD Study Group. N Engl J Med ;358: ADVANCE Collaborative Group. N Engl J Med 358: , Duckworth W for VADT. N Engl J Med 2009;360:129 :129-39
9 Cumulative Incidence of Any Predefined CV Outcome Cumulative Incidence of the First of Any of the Predefined CVD Outcomes Risk reduction 42% 95% CI: Log-rank p=0.016 Conventional treatment Intensive treatment No. at Risk Years Since Entry Intensive Conventional Nathan DM, et al. N Engl J Med 2005;353;
10 Myocardial Infarction Hazard Ratio (fatal or non-fatal MI or sudden death) Intensive (SU/Ins) vs Conventional Glucose Control MI HR=0.84 p=0.052 HR=0.85 p= HR (95%CI) HR Number of Events Con: Int: UKPDS 80. N Eng J Me 2008;359:
11 Meta-analysis: analysis: Major CVD Trials Number of Events (Annual Event Rate, %) More Intensive Less Intensive ΔA1c (%) Favours More Intensive Favours Less Intensive HR (95% CI) Major cardiovascular events ACCORD 352 (2.11) 371 (2.29) ( ) ADVANCE 557 (2.15) 590 (2.28) ( ) UKPDS 169 (1.30) 87 (1.60) ( ) VADT 116 (2.68) 128 (2.98) ( ) Overall 1,194 1, ( ) (Q=1.32, p=0.72, I 2 =0.0%) HR (95% CI) Turnbull FM, et al. Diabetologia 2009; 55:
12 Meta-analysis: analysis: All-cause Mortality Trials Number of Events (Annual Event Rate, %) More Intensive Less Intensive ΔA1c (%) Favours More Intensive Favours Less Intensive HR (95% CI) All-cause mortality ACCORD 257 (1.41) 203 (1.14) ( ) ADVANCE 498 (1.86) 533 (1.99) ( ) UKPDS 123 (0.13) 53 (0.25) ( ) VADT 102 (2.22) 95 (2.06) ( ) Overall ( ) (Q=5.71, p=0.13, I 2 =47.5%) HR (95% CI) Turnbull FM, et al. Diabetologia 2009; 55:
13 Sub-group Analysis for Major CVD Events: History of Macrovascular Disease Pre-specified Subgroups Number of Patients/Events More Intensive Less Intensive Favours More Intensive Favours Less Intensive HR (95% CI) p value for Test of Difference History of macrovascular disease Present 3,974/555 3,947/ ( ) 0.04 Absent 10,346/639 8,782/ ( ) HR (95% CI) p=0.04 Turnbull FM, et al. Diabetologia 2009; 55:
14 Glucose Paradox Glucose levels & hyperglycemic states are closely linked to increased CVD risk Definitive evidence that improving glucose control decreases major CVD events remains elusive Possible reasons: Intervention too late Studies too short, too small A1c difference too small
15 Comparison of ACCORD, ADVANCE, VADT Characteristic ACCORD ADVANCE VADT N 10,251 11,140 1,791 Mean Age Duration of T2DM 10 yr 8 yr 11.5 yr History of CVD 35% 32% 40% BMI Baseline A1C 8.3% 7.5% 9.4% Study Duration Target A1c <6% vs 7 8% 7 <6.5% vs Usual <6% vs 8 9% 8 Achieved A1c 6.4% and 7.5% 6.4% and 7.0% 6.9% and 8.4% ACCORD Study Group. N Engl J Med ;358: ADVANCE Collaborative Group. N Engl J Med 358: , Duckworth W for VADT. N Engl J Med 2009;360:129 :129-39
16 Glucose Paradox Glucose levels & hyperglycemic states are closely linked to increased CVD risk Definitive evidence that improving glucose control decreases major CVD events remains elusive Possible reasons: Intervention too late Studies too short, too small A1c difference too small Post prandial hyperglycemia Adverse CV effects (e.g. from hypoglycemia) Adverse effects of T2D drugs?? Mechanism specific? Excellent control of other risk factors
17 Blood Pressure, Lipid and Aspirin Therapy Study SBP mmhg LDL-C mg/dl (mmol/l) On Statins, % On Aspirin, % ACCORD 127/67 91 (2.35) ADVANCE 136/ (2.63) VADT 127/69 75 (1.94) SBP = systolic blood pressure; LDL-C C = LDL-cholesterol ADVANCE Collaborative Group. N Engl J Med 2008;358: ACCORD Study Group. N Engl J Med 2008;358: VADT Study Group. N Engl J Med 2009;360:
18 Achievement of Goals in US Diabetes Care A1C Survey Participants, % p=0.009 N Engl J Med 2013;368:
19 Achievement of Goals in US Diabetes Care Blood Pressure Survey Participants, % p=0.08 N Engl J Med 2013;368:
20 Achievement of Goals in US Diabetes Care LDL-Cholesterol Survey Participants, % p<0.001 N Engl J Med 2013;368:
21 Achievement of Goals in US Diabetes Care Smoking Status Survey Participants, % p=0.96 *self-report or cotinine >10 ng/ml N Engl J Med 2013;368:
22 Prevalence of Meeting A1C, BP, and LDL Goals Among People With Diabetes Percent % Diabetes Care Publish Ahead of Print February 15, 2013
23 Age-adjusted Death Rates for CVD USA,
24 Deaths due to diseases of the heart (United States: ) 1, Deaths in Thousands Years Go et al. Circulation. 2013;127:e6-e245
25 1,200 1, Deaths in Thousands Go et al. Circulation. 2013;127:e6-e245
26 Deaths in Thousands Males Females Go et al. Circulation. 2013;127:e6-e245
27 U.S. age standardized death rates* from cardiovascular diseases, Deaths per 100, Total CVD Stroke CHD Other CVD** Go et al. Circulation. 2013;127:e6-e245
28 Decline in Age Standardized Mortality Rates from 1997 to 2006 Comparison of a Diabetic Cohort with the UK general population Men Women Diabetic Nondiabetic The study included a cohort of 48,556 subjects with type 2 diabetes first diagnosed between 1996 and 2006, drawn from 197 family practices in the United Kingdom General Practice Research Database (UKGPRD). There were 6,630 deaths observed Gulliford & Charlton. Am J Epidemiol 2009;169:
29 Age-adjusted All-Cause Mortality Rates according to Diabetes Status, Gregg et al. Diabetes Care 35: , 2012
30 Age-adjusted CVD Mortality Rates according to Diabetes Status, Gregg et al. Diabetes Care 35: , 2012
31
32 Blood Pressure in Diabetes
33 ADA 2012
34 ADA 2013
35 ..there is no clear evidence of benefits in general from initiating antihypertensive drug treatment at SBP levels 140 mmhg (high normal BP), nor there is evidence of benefits from aiming at targets 130 mmhg. This is due to the lack of suitable studies correctly investigating these issues ESH/ESC Guidelines for the Management of Arterial Hypertension, European Heart Journal doi: /eurheartj/eht151
36 Ischemic CHD Mortality versus Usual BP Stratified by Age Prospective Studies Collaboration. Lancet. 2002;360:1903.
37 Clinical Trials of BP Lowering in Diabetic Patients: Mean Achieved Systolic (SBP) Trial N Mean SBP less intense Mean SBP more intense CVD Risk Reduction SHEP % Syst-EUR % HOT 1, % UKPDS 1, % ABCD No CVD ADVANCE 11, % mortality ACCORD 4, No CVD
38 ACCORD Blood Pressure Study Systolic Pressures (Mean + 95% CI) Mean # Meds Intensive: Standard: SBP (mm Hg) Average : Standard vs Intensive, Delta = N = Years Post-Randomization Intensive Standard ACCORD Study Group. N Engl J Med 2010; 362:
39 ACCORD Blood Primary Outcome Pressure Study Primary Outcome Nonfatal MI, (Nonfatal Stroke MI, or CVD Nonfatal Death Stroke, or CVD Death) 20 Patients with Events (%) Primary Outcome Nonfatal MI, Nonfatal Stroke or CVD Death HR = % CI ( ) HR = % CI ( ) Years Post-Randomization ACCORD Study Group. N Engl J Med 2010; 362:
40 ACCORD Study Group. N Engl J Med 2010; 362: ACCORD Blood Pressure Study Stroke Outcomes 20 Nonfatal Stroke 20 Total Stroke Patients with Events (%) HR = % CI ( ) Patients with Events (%) HR = % CI ( ) Years Post-Randomization Years Post-Randomization
41 Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes. Myocardial Infarction Journal of Hypertension.2011; 29:
42 Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes. Stroke Journal of Hypertension.2011; 29:
43 Intensive versus standard blood pressure control and all-cause mortality Bangalore, S. et al. Circulation 2011;123:
44 Intensive versus standard blood pressure control and stroke Bangalore, S. et al. Circulation 2011;123:
45 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension European Heart Journal doi: /eurheartj/eht151
46
47 Lipids in Diabetes
48 ADA/ACC Consensus Statement Treatment Goals in Patients With Cardiometabolic Risk and Lipoprotein Abnormalities Highest-risk patient Known CVD Diabetes plus 1 additional major CVD risk factor* High-risk patients No diabetes or known CVD but 2 major CVD risk factors* Diabetes but no other major CVD risk factors* LDL-C (mg/dl) Non HDL-C (mg/dl) Apo B (mg/dl) <70 <100 <80 <100 <130 <90 *Major risk factors beyond dyslipidemia include smoking, hypertension, and family history or premature CHD. ACC=American College of Cardiology; ADA=American Diabetes Association; Apo B=apolipoprotein B; CHD=coronary heart disease; CVD=cardiovascular disease; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol. Brunzell JD et al. Diabetes Care. 2008;31:
49 Lancet 2008; 371:
50 Lancet 2008;371:117 25
51 Lancet 2008;371:117 25
52 Lancet 2008;371:117 25
53 Lancet 2008;371:117 25
54 Lancet 2008;371:117 25
55 Lancet 2008;371:117 25
56 Lancet 2012; 380:
57 Lancet 2012; 380:
58 Lancet 2012; 380:
59 Vascular deaths avoided (per 1000) by 5-year risk & LDL cholesterol reduction Lancet 2012; 380:
60 Major vascular events avoided (per 1000) by 5-year risk & LDL cholesterol reduction Lancet 2012; 380:
61 Plasma Lipid Levels During Trial Total Cholesterol Placebo Fenofibrate LDL Cholesterol HDL Cholesterol Triglycerides ACCORD Study Group. N Engl J Med 2010; 362:
62
63 Aspirin Therapy in Diabetes
64 Anti-Platelet Therapy Consider aspirin therapy ( mg/day) as a primary prevention strategy in T1D or T2D at increased CVD risk (>10% over 10 yrs), including most men >50 years old and women >60 years old, with additional risk factors (family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria) Use aspirin therapy ( mg/day) as a secondary prevention strategy in those with diabetes with a history of CVD. For patients with CVD and aspirin allergy, clopidogrel (75 mg/day) should be used Combination therapy with aspirin ( mg/day) and clopidogrel (75 mg/day) is reasonable for up to 1 year after an acute coronary episode American Diabetes Association. Diabetes Care. 2013; 36 (suppl 1):S11 :S11-S66S66
65 Aspirin for Primary Prevention serious vascular events dropped from 0 57% to 0 51% 0 per year by the use of aspirin risk of major bleeds increased from 0 07% 0 07% to 0 10% 0 per year by the use of aspirin. Antithrombotic Trialists (ATT) Collaboration; Lancet 2009; 373:
66 Serious Vascular Events Antithrombotic Trialists (ATT) Collaboration; Lancet 2009; 373:
67
68 Microvascular Outcomes in T2D
69 Microvascular Outcomes in T2D Trials Nephropathy Retinopathy Neuropathy VADT ACCORD ADVANCE (albuminuria) (albuminuria) (albuminuria) +/-
70 Effects of Intensive vs Standard Therapy for Glycemia on Microvascular End Points in ACCORD, Pretransition and Over 5 years (selected outcomes) End point Pretransition, HR (95% CI) Total follow-up, HR (95% CI) Microalbuminuria 0.79 ( ) 0.90) p= ( ) 0.94) p= Cataract surgery 0.90 ( ) p= ( ) 0.99) p= line change in visual acuity 0.84 ( ) 0.97) p= ( ) p= Loss of ankle jerk during Jendrassik maneuver 0.94 ( ) p= ( ) 0.97) p=0.005 Loss of pressure sensation 0.88 ( ) p= ( ) 0.95) p= Lancet 2010; 376:
71
72 ACCORD Eye Study N Engl J Med 2010;363:233-44
73 Intensive Glucose Control and Renal End Points in T2D Meta-analysis analysis Coca et al. Arch Intern Med 2012; 172:
74 Intensive Glucose Control and Renal End Points in T2D Meta-analysis 7 RCTs of intensive vs. conventional glucose control (ACCORD, ADVANCE, Kumamoto, UKPDS 33, UKPDS 34, VADT, VA-Feasibility) Median follow-up 2 to 11 years Mean duration of DM 6.5 to 12 yrs (except UKPDS) Outcomes Microalbuminuria, Macroalbuminuria Doubling of Serum Creatinine, ESRD, Renal Death Coca et al. Arch Intern Med 2012; 172:
75
76
77 Pooled risk ratios for renal endpoints Event Risk Ratio (95% CI) Microalbuminuria 0.86 ( ) Macroalbuminuria 0.74 ( ) Cr doubling 1.06 ( ) ESRD 0.69 ( ) Renal death 0.99 ( ) Coca et al. Arch Intern Med (2012); 172:
78 American Journal of Kidney Diseases 2012; 60:
79 New onset microalbuminuria New onset macroalbuminuria Doubling of serum creatinine
80 All cause mortality Cardio vascular mortality End stage renal disease
81
82 Conclusions Reducing the complications of type 2 diabetes requires attention to multiple risk factors glycemia, blood pressure, lipids, smoking cessation.
The Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationA Fork in the Road: Navigating Through New Terrain
A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for Diabetes
More informationComplications of Diabetes: Screening and Prevention
Complications of Diabetes: Screening and Prevention Dr Steve Cleland Consultant Physician GGH and QEUH Diabetes Staff Education Course June 17 Diabetic Complications Microvascular: Retinopathy Nephropathy
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationSlide 1. Slide 2. Slide 3. A Fork in the Road: Navigating Through New Terrain. Diabetes Standards of Care Then and Now
Slide 1 A Fork in the Road: Navigating Through New Terrain Carol Hatch Wysham, MD Clinical Associate Professor of Medicine University of Washington School of Medicine Section Head, Rockwood Center for
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationMicrovascular Complications in Diabetes:
Microvascular Complications in Diabetes: Perspectives on Glycemic Control to Prevent Microvascular Complications Discussion Outline: Glycemia and Microvascular Compliations Clinical Trials - A Brief History
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationIndividualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus
1 Dissertation Title Page: Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus Qian Shi, MPH, PhD candidate Department of Global Health Management
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationPrevention of complications: are we winning or losing the battle. Naveed Sattar Professor of Metabolic Medicine
Prevention of complications: are we winning or losing the battle Naveed Sattar Professor of Metabolic Medicine Duality of Interest Declaration Consultant or speaker for: Amgen, AstraZeneca, Boehringer
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationCardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes
Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes Following this presentation, you will be able to: Describe the relationship between major CV risk factors and CVD outcomes Select
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationThe Burden of the Diabetic Heart
The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationPrevention of MACROvascular Complications of Diabetes
Prevention of MACROvascular Complications of Diabetes Matt Bouchonville, MD, CDE Endocrinology Division University of New Mexico School of Medicine July 12, 2018 Conflicts of Interest None Objectives 1.
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationGlucose and CV disease
Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationSESSION 5 2:20 3:35 PM
SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More information1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial?
Jeff D. Williamson, MD, MHS Chief, Geriatric Medicine Sticht Center on Aging 1. How does the response to therapy compare in elderly versus middle age adults with diabetes in a randomized trial? 2. Are
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationFibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr
Fibrate and cardiovascular disease: Evident from meta-analysis Thongchai Pratipanawatr ??? ย คห นใหม ย คห นกลาง ย คห นเก า ?? Statin era? ย คห นใหม ย คห นกลาง ย คห นเก า CURRENT ROLE OF FIBRATE What are
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationReview. Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction
Review Hyperglycemia, dyslipidemia and hypertension in older people with diabetes: the benefits of cardiovascular risk reduction Diabetes mellitus is increasingly recognized as an essentially vascular
More informationDiabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationHypertension Management in Diabetic Patients
Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationHeart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People
November September 23, 20, 20102012 Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People Eva Lonn, Jackie Bosch, Jane Castelli, Andrea
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationCV Risk Management in Diabetes Mellitus
CV Risk Management in Diabetes Mellitus J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine University of California, San Francisco Mr. B 40 y/o Latino male c/o fatigue,
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationAggressive Lipid Management for Diabetes
Aggressive Lipid Management for Diabetes Practical Ways to Achieve Targets in Diabetes Care Keystone, CO July 16, 2011 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and Biophysics
More informationGlycemic control a matter of life and death
Glycemic control a matter of life and death Linda Garcia Mellbin MD PhD Specialist in Cardiology & Internal medicine Dep of Cardiology Karolinska University Hospital /Karolinska Institutet Mortality (%)
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More information